Эра иммуноонкологии в онкоурологии: чего мы достигли? Обзор симпозиума альянса компаний «Мерк» и «Пфайзер», состоявшегося в рамках XXV Российского онкологического конгресса. 9 ноября 2021 г.
- Выпуск: Том 23, № 4 (2021)
- Страницы: 578-587
- Раздел: КЛИНИЧЕСКАЯ ОНКОЛОГИЯ
- URL: https://journals.rcsi.science/1815-1434/article/view/100147
- DOI: https://doi.org/10.26442/18151434.2021.4.201315
- ID: 100147
Цитировать
Полный текст
Аннотация
В рамках XXV Российского онкологического конгресса 9 ноября 2021 г. состоялся симпозиум, в ходе которого обсуждались различные вопросы тактики медикаментозного и хирургического лечения метастатического почечно-клеточного рака и уротелиального рака. В настоящее время появляются новые препараты, проводятся крупные клинические исследования, открываются новые перспективы иммунотерапии злокачественных новообразований. Одна из новых опций – ингибиторы контрольных точек иммунного ответа. На симпозиуме были представлены результаты двух исследований – JAVELIN Renal 101 и JAVELIN Bladder 100, уточняющие эффективность и безопасность ингибитора PD-L1 авелумаба. Симпозиум проводился при поддержке альянса компаний «Мерк» и «Пфайзер».
Полный текст
Открыть статью на сайте журналаСписок литературы
- Злокачественные новообразования в России в 2020 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2021 [Zlokachestvennye novoobrazovaniia v Rossii v 2020 g. (zabolevaemost' i smertnost'). Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow, 2021 (in Russian)].
- Leilei Ai, Jian Chen, Hao Yan, et al. Drug Des Devel Ther. 2020;14:3625-49. doi: 10.2147/DDDT.S267433
- Choueiri TK, Rini BI, Larkin JMG, et al. Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). 2017 ASCO Annual Meeting I. Abstract TPS4594.
- Motzer R. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Abstract LBA6_PR (oral presentation).
- Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1103-15. doi: 10.1056/NEJMoa1816047
- Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030-9. doi: 10.1016/j.annonc.2020.04.010
- Haanen J, Larkin J, Choueiri TK, et al. Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. 2021 ASCO Annual Meeting I. Abstract 4574.
- Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;17:3068-77. doi: 10.1200/JCO.2000.18.17.3068
- Dogliotti L, Cartenì G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52:134-41. doi: 10.1016/j.eururo.2006.12.029
- De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191-9. doi: 10.1200/JCO.2011.37.3571
- Sonpavde GP, Mariani L, Lo Vullo S, et al. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. J Urol. 2018;200(6):1207-14. doi: 10.1016/j.juro.2018.07.035
- NCCN Guidelines: Bladder Cancer, V6.2020. Available at: https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf. Accessed: 15.11.2021
- Von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-8. doi: 10.1200/JCO.2005.07.757
- Bajorin DF, Dodd PM, Mazumbar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-81. doi: 10.1200/JCO.1999.17.10.3173
- Grivas P, Monk BJ, Petrylak D, et al. Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Target Oncol. 2019;14:505-25. doi: 10.1007/s11523-019-00665-1
- Galluzzi L, Buqué A, Kepp O, et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28:690-714. doi: 10.1016/j.ccell.2015.10.012
- De Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res. 2014;20:5384-91. doi: 10.1158/1078-0432.CCR-14-1298
- Powles T, Park SH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383:1218-30. doi: 10.1056/NEJMoa2002788
- Powles T, Park SH, Voog E, et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. 2020 ASCO Annual Meeting II. Abstract LBA1 (oral presentation).
- Grivas P, Park SH, Voog E, et al. 704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100. Ann Oncol. 2020;31(Suppl. 4):S555-6. doi: 10.1016/j.annonc.2020.08.776
- Sridhar SS, Powles T, Loriot Y, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance. 2021 ASCO Annual Meeting I. Abstract 4527.
- Powles T, Petrylak DP, Park SH, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial. 2021 ASCO Annual Meeting I. Abstract 4520.
- Grivas P, Park SH, Voog E, et al. Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100. 2021 ASCO Annual Meeting I. Abstract 4525.
- Kelly K, Infante JR, Taylor H, et al. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018;124(9):2010-7. doi: 10.1002/cncr.31293
- Fradet Y, Bellmut J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970-6. doi: 10.1093/annonc/mdz127
- Galsky MD, Arija JAA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547-57. doi: 10.1016/S0140-6736(20)30230-0
- Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2
- Vuky J, Balar AV, Castellano D, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2020;38(23):2658-66. doi: 10.1200/JCO.19.01213
- National Comprehensive Cancer Network. Available at: www.nccn.org. Accessed: 15.11.2021
- European Society for Medical Oncology. Available at: www.esmo.org. Accessed: 15.11.2021.
- Bajorin D, Witjes JA, Gschwend J, et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). Genitourinary Cancers Symposium, 2021.
- NCCN Guidelines Version 4.2021: Kidney Cancer.
- Носов Д.А., Гладков О.А., Волкова М.И., и др. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2020;11:513-22 [Nosov DA, Gladkov OA, Volkova MI, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu pochechnokletochnogo raka. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2020;11:513-22 (in Russian)]. DOI:10.18027 / 2224-5057-2020-10-3s2-31